Kenvue, a subsidiary of Johnson & Johnson, traded its shares on the New York Stock Exchange in 2023 following a recent production issue involving its flagship analgesic, Tylenol. The company is currently grappling with a significant supply disruption impacting the availability of the medication. Kenvue has initiated a comprehensive investigation into the root cause of the problem, assessing production efficiencies and inventory levels. Regulatory authorities are involved in assessing the situation and ensuring product safety. The company is focusing on restoring normal operations and mitigating potential impacts on consumers.
Credits: NYT > Top Stories
